Revolution Medicines (RVMD) Retained Earnings (2019 - 2026)
Revolution Medicines' (RVMD) quarterly Retained Earnings came in at -$622000.0 in Q1 2026, up 99.97% year-on-year from -$311048.4 in Q1 2025, and down 119.22% quarter-over-quarter from $3.2 million in Q4 2025.
Revolution Medicines (RVMD) Retained Earnings (2019 - 2026) Analysis & Trends
Revolution Medicines' Retained Earnings history runs 8 years deep, the most recent figure standing at -$622000.0 for Q1 2026.
- On a quarterly basis, Retained Earnings rose 99.97% year-over-year to -$622000.0 in Q1 2026; TTM through Mar 2026 was -$622000.0, a 99.97% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 145.04% from the prior year.
- Retained Earnings retreated to -$622000.0 in Q1 2026 per RVMD's latest filing, from $3.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at $3.2 million in Q4 2025 and bottomed at -$2.5 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$2.4 million (2022), against an average of -$704.2 million.
- Across the five-year window, Retained Earnings sank 177079.33% in 2024 and jumped 145.04% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$701.3 million in 2022, then jumped by 100.08% to $544000.0 in 2023, then jumped by 142.83% to $1.3 million in 2024, then jumped by 145.04% to $3.2 million in 2025, then sank by 119.22% to -$622000.0 in 2026.
- Per Business Quant, the three latest RVMD Retained Earnings figures stand at -$622000.0 (Q1 2026), $3.2 million (Q4 2025), and -$2.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | -24.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -622,000.00 |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | -2.50 Bn |
| Jun 30, 2025 | -2.20 Bn |
| Mar 31, 2025 | -2.00 Bn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | -1.54 Bn |
| Jun 30, 2024 | -1.39 Bn |
| Mar 31, 2024 | -1.20 Mn |
| Dec 31, 2023 | 544,000.00 |
| Sep 30, 2023 | -871,000.00 |
| Jun 30, 2023 | -867.70 Mn |
| Mar 31, 2023 | -769.40 Mn |
| Dec 31, 2022 | -701.34 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -1.77 Mn |
| Mar 31, 2022 | -1.28 Mn |
| Dec 31, 2021 | -452.64 Mn |
| Sep 30, 2021 | -399.96 Mn |
| Jun 30, 2021 | -347.02 Mn |